In vitro and in vivo inhibition of LPS-stimulated tumor necrosis factor-α secretion by the gallotannin β-D-pentagalloylglucose

Ken S. Feldman, Kiran Sahasrabudhe, Michael D. Lawlor, Sarah L. Wilson, Charles H. Lang, William J. Scheuchenzuber

Research output: Contribution to journalArticlepeer-review

51 Scopus citations

Abstract

The naturally occurring gallotannin β-D-pentagalloylglucose (β-PGG) decreases tumor necrosis factor-alpha (TNF-α) output from human peripheral blood mononucleocytes exposed to lipopolysaccharide (LPS) by as much as 90% (vs control) at ∼5 μM concentration. A qualitatively similar but less pronounced effect (∼50% decrease) was observed in the serum of rats dosed with both LPS and β-PGG. These results may have relevance to therapies that target disease states characterized by an overproduction of TNF-α.

Original languageEnglish (US)
Pages (from-to)1813-1815
Number of pages3
JournalBioorganic and Medicinal Chemistry Letters
Volume11
Issue number14
DOIs
StatePublished - Jul 23 2001

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Biology
  • Organic Chemistry
  • Drug Discovery
  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'In vitro and in vivo inhibition of LPS-stimulated tumor necrosis factor-α secretion by the gallotannin β-D-pentagalloylglucose'. Together they form a unique fingerprint.

Cite this